

Reference list

1. van Rossum IAM, Vos S, JBM, Burns LMPH, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology* 2012;79:1809-1816.
2. Prins ND, Van Der Flier WM, Brashear HR, Barkhof F, Scheltens P. Predictors of progression from mild cognitive impairment to Alzheimer's disease in the placebo arm of a clinical trial population. *Journal of Nutrition, Health and Aging* 2012;16:826.
3. Xu WL, Caracciolo B, Wang HX, Santoni G, Winblad B, Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia among APOE epsilon4epsilon4 carriers. *Journal of Alzheimer's disease : JAD* 2013;33:507-515.
4. Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. *Archives of neurology* 2007;64:862-871.
5. Elcoroaristizabal Martin X, Fernandez Martinez M, Galdos Alcelay L, et al. 8,6 Progression from amnesic mild cognitive impairment to Alzheimer's disease: ESR1 and ESR2 polymorphisms and APOE gene. *Dementia and geriatric cognitive disorders* 2011;32:332-341.
6. Viticchi G, Falsetti L, Vernieri F, et al. A polipoprotein E Genotype and Cerebrovascular Alterations Can Influence Conversion to Dementia in Patients with Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD* 2014.
7. Squitti R, Ghidoni R, Siotto M, et al. Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. *Annals of*

neurology 2014;75:574-580.

8. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology* 2010;75:230-238.

9. Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. *Archives of neurology* 2005;62:975-980.

10. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. *Archives of general psychiatry* 2011;68:961-969.

11. Chu LW. Clinical, cognitive, neuropsychiatric and genetic predictors of conversion from amnesic mild cognitive impairment to Alzheimer's disease in Chinese older adults. *Alzheimer's and Dementia* 2011;7:S349.

12. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. *Neurology* 2011;77:1619-1628.

13. Forlenza OV, Diniz BS, Teixeira AL, et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. *World Journal of Biological Psychiatry* 2010;11:774-780.

14. Ravaglia G, Forti P, Maioli F, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk

factors. *Dementia and geriatric cognitive disorders* 2006;21:51-58.

15. Diniz BS, Teixeira AL, Ojopi EB, et al. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 2010;22:1305-1311.

16. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. *JAMA : the journal of the American Medical Association* 1995;273:1274-1278.

17. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). *Archives of gerontology and geriatrics* 2007;44 Suppl 1:155-165.

18. Sepe-Monti M, Pantano P, Vanacore N, et al. 21,33 Vascular risk factors and white matter hyperintensities in patients with amnesic mild cognitive impairment. *Acta neurologica Scandinavica* 2007;115:419-424.

19. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. *Neurology* 2007;68:828-836.

20. Jack CR, Jr., Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain : a journal of neurology* 2010;133:3336-3348.

21. Kantarci K, Weigand SD, Przybelski SA, et al. Risk of dementia in MCI:

combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. *Neurology* 2009;72:1519-1525.

22. Somme J, Fernandez-Martinez M, Molano A, Zarranz JJ. Neuropsychiatric symptoms in amnesic mild cognitive impairment: increased risk and faster progression to dementia. *Current Alzheimer research* 2013;10:86-94.

23. McEvoy L, Heister D, Blennow K, Brewer J, Dale A. Predicting progression to alzheimer's disease in MCI using combined structural imaging and CSF biomarkers. *Alzheimer's and Dementia* 2011;7:S3-S4.

24. Chu L. Low BMI predicts incident Alzheimer's disease in older adults with amnesic mild cognitive impairment: A three-year prospective cohort study. *Alzheimer's and Dementia* 2012;8:P323.

25. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. *Neurology* 2007;68:1596-1602.

26. Ye BS, Seo SW, Cho H, et al. Effects of education on the progression of early- versus late-stage mild cognitive impairment. *International psychogeriatrics / IPA* 2013;25:597-606.

27. Farias STP, Mungas DP, Reed BRP, Harvey DP, DeCarli CMD. 30,44 Progression of Mild Cognitive Impairment to Dementia in Clinic- vs Community-Based Cohorts. *Archives of neurology* 2009;66:1151-1157.

28. Zhou B, Nakatani E, Teramukai S, Nagai Y, Fukushima M. Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. *Journal of*

Alzheimer's disease : JAD 2012;30:367-375.

29. Desikan RS, Cabral HJ, Fischl B, et al. Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. *AJNR American journal of neuroradiology* 2009;30:532-538.

30. Amieva H, Letenneur L, Dartigues JF, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. *Dementia and geriatric cognitive disorders* 2004;18:87-93.

31. Fellows L, Bergman H, Wolfson C, Chertkow H. Can clinical data predict progression to dementia in amnesic mild cognitive impairment? *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques* 2008;35:314-322.

32. Rozzini L, Chilovi BV, Bertolotti E, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnesic mild cognitive impairment. *International journal of geriatric psychiatry* 2006;21:550-555.

33. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. *Neurocase* 2005;11:3-7.

34. Li L, Wang Y, Yan J, et al. Clinical predictors of cognitive decline in patients with mild cognitive impairment: the Chongqing aging study. *Journal of neurology* 2012;259:1303-1311.

35. Alegret M, Cuberas-Borros G, Espinosa A, et al., Cognitive, Genetic, and Brain

Perfusion Factors Associated with Four Year Incidence of Alzheimer's Disease from Mild Cognitive Impairment. *Journal of Alzheimer's disease* : JAD 2014.

36. Rozzini L, Chilovi BV, Conti M, et al. Conversion of amnesic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. *International journal of geriatric psychiatry* 2007;22:1217-1222.

37. Wang P-N, Hong C-J, Lin K-N, Liu H-C, Chen W-T. APOE [epsilon]4 increases the risk of progression from amnesic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan. *Journal of Neurology, Neurosurgery & Psychiatry* 2011;82:165-169.

38. Chan WC, Lam LCW, Tam CWC, et al. Neuropsychiatric symptoms are associated with increased risks of progression to dementia: a 2-year prospective study of 321 Chinese older persons with mild cognitive impairment. *Age & Ageing* 2011;40:30-35.

39. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. *Neurology* 2004;63:1882-1891.

40. DeCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. *Neurology* 2004;63:220-227.

41. Geroldi C, Rossi R, Calvagna C, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. *Journal of neurology, neurosurgery, and psychiatry* 2006;77:1219-1222.

42. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S. Risk of

developing dementia in people with diabetes and mild cognitive impairment. *The British journal of psychiatry : the journal of mental science* 2010;196:36-40.

43. van Rossum IA, Visser PJ, Knol DL, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 2012;29:319-327.

44. Staekenborg SSMD, Koedam ELGEMD, Henneman WJPMD, et al. Progression of Mild Cognitive Impairment to Dementia: Contribution of Cerebrovascular Disease Compared With Medial Temporal Lobe Atrophy. *Stroke; a journal of cerebral circulation* 2009;40:1269-1274.

45. Vemuri P, Weigand SD, Knopman DS, et al. Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. *NeuroImage* 2011;54:985-991.

46. Richard E, Schmand B, Eikelenboom P, et al. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. *Dementia and geriatric cognitive disorders* 2012;33:204-209.

47. Straaten EC, Harvey D, Scheltens P, et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. *Journal of neurology [serial online]* 2008;255:1302-1308.

Available at:

<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/530/CN-00666530/frame.html>

<http://link.springer.com/article/10.1007%2Fs00415-008-0874-y>.

48. Xu W, Caracciolo B, Wang H-X, et al. Accelerated Progression From Mild Cognitive Impairment to Dementia in People With Diabetes. *Diabetes* 2010;59:2928-2935.

49. Clerici F, Caracciolo B, Cova I, et al. Does vascular burden contribute to the progression of mild cognitive impairment to dementia? *Dementia and geriatric cognitive disorders* 2012;34:235-243.

50. Viticchi G, Falsetti L, Vernieri F, et al. Vascular predictors of cognitive decline in patients with mild cognitive impairment. *Neurobiology of aging* 2012;33:1127.e1121-1127.e1129.

51. Barnes DE, Cenzer IS, Yaffe K, Ritchie CS, Lee SJ. A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2014.

52. Panza F, Capurso C, D'Introno A, et al. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. *The Italian Longitudinal Study on Aging. International journal of geriatric psychiatry* 2008;23:726-734.

53. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. *Archives of neurology* 2004;61:1290-1293.

54. Richard EMDP, Reitz CMDP, Honig LHMDP, et al. Late-Life Depression, Mild Cognitive Impairment, and Dementia. *JAMA neurology* 2013;70:383-389.

55. Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. *Journal of Alzheimer's disease : JAD* 2012;31:265-275.
56. Ramakers IHGB, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. *Psychological Medicine* 2010;40:1193-1201.
57. Golimstok A, Fernandez C, Campora N, et al. Impact of disinhibition and apathy on progression from mild cognitive impairment to dementia. *Alzheimer's and Dementia* 2013;9:P772.
58. Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer's Disease Neuroimaging I. Extension and refinement of the predictive value of different classes of markers in ADNI: Four-year follow-up data. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2014;10(6):704-12 doi: 10.1016/j.jalz.2013.11.009[published Online First: Epub Date].
59. Jack CR, Jr., Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnesic MCI. *Neurology* 2005;65:1227-1231.
60. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. *Journal of Alzheimer's disease : JAD* 2010;21:1119-1128.

61. Cabranes JA, De Juan R, Encinas M, et al. 15 Relevance of functional neuroimaging in the progression of mild cognitive impairment. *Neurological research* 2004;26:496-501.
62. Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. *The American journal of psychiatry* 2000;157:1399-1405.
63. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2004;171:863-867.
64. Dierckx E, Engelborghs S, De Raedt R, et al. Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment. *International journal of geriatric psychiatry* 2009;24:1094-1100.
65. Edwards ER, Spira AP, Barnes DE, Yaffe K. Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia. *International journal of geriatric psychiatry* 2009;24:716-722.
66. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease. *Archives of neurology* 2006;63:1763-1769.
67. Devine ME, Fonseca JAS, Walker Z. Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia? *International Psychogeriatrics* 2013;25:120-127.

68. Chu L. Serum clusterin levels and the risk of Alzheimer's disease in chinese older adults with amnesic mild cognitive impairment: A three-year prospective cohort study. *Alzheimer's and Dementia* 2012;8:P282.
69. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. *The Italian Longitudinal Study on Aging. Neurobiology of aging* 2011;32:1932-1941.
70. Defrancesco M, Marksteiner J, Deisenhammer E, Kemmler G, Djurdjevic T, Schocke M. Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 2013;34:665-672.
71. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. 29 Mediterranean diet and mild cognitive impairment. *Archives of neurology* 2009;66:216-225.
72. Podea DM, Chenderes RM, Nanu PD, Mila C. Atrial fibrillation and the risk for conversion from mild cognitive impairment to dementia in subjects aged over 65. *European Psychiatry* 2010;25.
73. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. *Neurology* 2011;76:247-252.
74. Encinas M, De Juan R, Marcos A, et al. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease. *European journal of nuclear medicine and molecular imaging*

2003;30:1473-1480.

75. Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnesic mild cognitive impairment. *Neurology* 2005;64:902-904.

76. Reitz C, MDP, Mayeux R, MDM, Luchsinger J, MDP. Antihypertensive Medications Influence the Rate of Conversion From Mild Cognitive Impairment to Alzheimer Disease. *Archives of neurology* 2008;65:994-995.

77. Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. *Clinical neurology and neurosurgery* 2006;108:733-736.

78. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. *Archives of general psychiatry* 2006;63:916-924.

79. Devanand DP, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS. MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. *NeuroImage* 2012;60:1622-1629.

80. Zhu J, Wang Y, Li J, Deng J, Zhou H. Intracranial artery stenosis and progression from mild cognitive impairment to Alzheimer disease. *Neurology* 2014;82:842-849.

81. Clerici F, Caracciolo B, Cova I, et al. The impact of vascular burden on the progression of MCI to dementia. *Journal of neurology* 2010;257:S165-S166.

82. Gross AL, Manly JJ, Pa J, et al. Cortical signatures of cognition and their relationship to Alzheimer's disease. *Brain imaging and behavior* 2012;6:584-598.

83. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. *Journal of neurology, neurosurgery, and psychiatry* 2005;76:1479-1484.
84. Chu LW, Yik PY, Kwan F, Chan C, Ha J, Lam KS. Leptin and the risk of progression to Alzheimer's disease among Chinese older adults with amnesic mild cognitive impairment. *Journal of the neurological sciences* 2013;333:e317.
85. Ettorre E, Cerra E, Marigliano B, et al. Role of cardiovascular risk factors (CRF) in the patients with mild cognitive impairment (MCI). *Archives of gerontology and geriatrics* 2012;54:330-332.
86. Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. *International journal of clinical practice* 2008;62:1070-1075.
87. Ghidoni R, Benussi L, Glionna M, et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. *Journal of Alzheimer's disease : JAD* 2010;22:985-991.
88. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. *Neurology* 2009;73:754-760.
89. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet neurology* 2006;5(3):228-34 doi: 10.1016/s1474-4422(06)70355-6[published Online First: Epub

Date]].

90. Ma F, Wu T, Miao R, Xiao YY, Zhang W, Huang G. Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up. *Journal of Alzheimer's disease* : JAD 2015;43(4):1441-9 doi: 10.3233/jad-141566[published Online First: Epub Date]].

91. Inzelberg R, Massarwa M, Schechtman E, Strugatsky R, Farrer LA, Friedland RP. Estimating the Risk for Conversion from Mild Cognitive Impairment to Alzheimer's Disease in an Elderly Arab Community. *Journal of Alzheimer's disease* : JAD 2015 doi: 10.3233/jad-142871[published Online First: Epub Date]].